The 2nd Gene Therapy Immunogenicity Summit is the industry’s definitive forum enabling you to better modulate, measure and predict immune response to your gene therapy candidate.

In the context of ever-increasing gene therapy clinical activity and uncertainty around immunogenicity challenges, the Gene Therapy Immunogenicity Summit will unite large pharma and innovative biotechs to ensure that you’re up to speed on the latest approaches to predict, measure and overcome every immunogenicity challenge you encounter.

Focused specifically on examining gene therapy immunogenicity, this event will enable you to learn how to evaluate and overcome pre-existing immunity to AAV vectors, understand how immune-modulatory approaches could enable re-dosing and learn the reality of regulatory expectations around immunological assays.

Incorporating insights from leading immunological, bioanalytical and translational experts, this is your opportunity to gain extensive technical information on the contrasts between immunogenicity encountered across organs and administration routes, how models can be enhanced to enable comparative immunology between species and what the latest clinical data tells us about how to adapt existing approaches to address immunogenicity.